Can two diabetes drugs save kidneys after cancer surgery?
NCT ID NCT06818305
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at whether two drugs, finerenone and empagliflozin, can slow kidney function decline in people at high risk for chronic kidney disease after having a kidney removed for cancer. Ten participants took one or both drugs or no drug for a year. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Finerenone and Empagliflozin (drugs)
- What this could lead to
- If successful, this could point toward a way to slow kidney function loss in patients who had a kidney removed due to cancer.
- What could go wrong
- This is a very small, early-phase study (only 10 participants) that was terminated, so results are limited. The drugs may not work better than standard care and carry risks like high potassium, low blood pressure, or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing
Nanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Plastics in dialysis: could they add toxins to Children's blood?
- Can a newer heart failure drug protect kidneys better than an older one?
- A urine test strip that could transform kidney diet care?
- A little reward, a bigger impact: do gift cards boost kidney donor Follow-Up?
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Triple therapy takes on rare, aggressive kidney cancer